Prevalence of AGER gene polymorphism in post menopause Iraqi sample with Osteoporosis and osteopenia in type 2DM
DOI:
https://doi.org/10.31351/vol31iss2pp202-210Keywords:
Osteoporosis, RAGE gene polymorphismsAbstract
Osteoporosis (OP)is one of the most important metabolic disorder also affected by interaction of genetic and environmental factors by almost 70% and 30% respectively. Genetic components are identified to strongly effect bone mineral density, bone building and turnover, so they play an important role in determining risk of OP and fragility fractures. This study consists of patient and control group; Group A: (70) postmenopausal women with OP and osteopenia, Group B: (20) control group. five milliliters of blood sample were divided into three tubes; one tube (1ml) contain gel for obtain serum to measure glucose level, the others tubes containing ethylene-diamine-tetra-acetic acid (EDTA), in 2 tube 2ml stored in deep freeze at (–40 Co) until genomic analysis of DNA for the performance of PCR genotyping of gene polymorphisms of RAGE, in 3 tube 2ml used to perform Glycated Hemoglobin % (HbA1c) assays. HbA1c and Serum glucose levels is significantly increased in Group A. a high prevalence of RAGE polymorphism rs1800625 and rs1800624 were detected in postmenopausal women with OP with type2DM. Homozygous 1800625 were (31%) and heterozygous 1800625(31%) compared to control homozygous 1800625 were (5%) and heterozygous 1800625 were (5%) respectively. Homozygous 1800624 were (28.5%) and heterozygous 1800624(28.5%) compared to control homozygous 1800624 were (5%) and heterozygous 1800624 were (20%) respectively. In conclusion, the rs1800625 and rs1800624 polymorphism might be a causal risk allele for OP in post menopause Iraqi women with type2 DM.
References
Tamer A, Gheita H, and Nevin H. Epidemiology and awareness of osteoporosis: a viewpoint from the Middle East and North Africa. Int. J. Clin. Rheumatol. 2018; 13(3): 134-147.
Rivadeneira F, Mäkitie O. Osteoporosis and bone mass disorders: from gene pathways to treatments. Trends Endocrinol Metab.2016; 27:262–281.
Hussein EA, Kadhim DJ and Al-Auqbi TF. Belief About Medications Among Type 2 Diabetic Patients Attending the National Diabetes Center in Iraq. Iraqi J Pharm Sci, 2017;26(2).
Leidig-Bruckner G, Grobholz S, Bruckner T, et al. Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus. BMC Endocr Disord, 2014; 14:33.
Ali IA, and Ali SH. Impact of Osteocalcin Level on Vascular Calcification in Type 2 Diabetics in Relation to Fibroblast Growth Factor-23(FGF-23) Iraqi J Pharm Sci, 2018;27(2).
Rungratanawanich W, Qu Y, Wang X et al. Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury, Experimental & Molecular Medicine 2021;53:168–188.
Yang D, Chiang T, Chang I, et al. Increased Levels of Circulating Advanced Glycation End-Products in Menopausal Women with Osteoporosis, International Journal of Medical Sciences 2014; 11(5): 453-460.
Otta C, Jacobsb K, Hauckec E, et al. Role of advanced glycation end products in cellular signaling, Redox Biology, 2014; 411–429.
Serveaux-Dancer M, Jabaudon M, Creveaux I, Belville C, et al. Pathological Implications of Receptor for Advanced Glycation End-Product (AGER) Gene Polymorphism, Hindawi Disease Markers Volume 2019; 17: 2067353.
Barham D, Trinder P. An improved color reagent from the determination of blood glucose by the oxidative system. Analyst. 1972; 97: 142-145.
Abraham EC, Huff TA, Cope ND, et al. Determination of the glycosylated hemoglobin (HbA1) with a new micro column procedure, suitability of the technique for assessing the clinical management of diabetes mellitus. Diabetes 1978; 27(9): 931-937.
Sanger F, Coulson AR. A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol 1975; 94:44.
AL-Azzawie AF, Husain WN, Salih MH, AL-Assie AH. The relationship between some electrolyte levels and MTHFR C667T gene polymorphism, Eurasia J Biosci 2020;14, 545-551
Yaturu S, Humphrey S, Landry C, Jain SK. Decreased bone mineral density in men with metabolic syndrome alone and with type 2 diabetes. Med Sci Monit 2009; 15: CR5-CR9.
Deng X, Xu M, Shen M, Cheng J. Effects of type 2 diabetic serum on proliferation and osteogenic differentiation of mesenchymal stem cells. J Diabetes Res. 2018:1-9.
Zhou Y, Li Y, Zhang D, Wang J, and Yang H, “Prevalence and predictors of osteopenia and osteoporosis in postmenopausal Chinese women with type 2 diabetes,” Diabetes Research and Clinical Practice, 2010;(90);3:261–269.
Wongdee K, Charoenphandhu N. Osteoporosis in diabetes mellitus: Possible cellular and molecular mechanisms. World J Diabetes 2011; 2(3): 41-48.
Zhou Z, Xiong WC: RAGE and its ligands in bone metabolism. Front Biosci (Schol Ed). 2011 Jan 1; 3:768-76.
Zheng Z, Wen-Cheng X. RAGE and its ligands in bone metabolism, Frontiers in Bioscience ,2011; S3:768-776.
Galliera E, Marazzi MG, Gazzaruso C, Gallotti P, et al. Evaluation of circulating sRAGE in osteoporosis according to BMI, adipokines and fracture risk: a pilot observational study. Immun Ageing 2017; 14:13.
Dachun Y, and Michael B, Hyperglycemia-Induced Reactive Oxygen Species Increase Expression of the Receptor for Advanced Glycation End Products (RAGE) and RAGE Ligands Diabetes 2010; 59(1): 249-255.
Al Anouti F, Taha Z, Shamim S, Khalaf K, et al. An insight into the paradigms of osteoporosis: From genetics to biomechanics. Bone reports, 2019;100216.
Ying Z, Nan J, Feng H, Naijun Fan, X et al. Association of single-nucleotide polymorphisms in the RAGE gene and its gene- environment interactions with diabetic nephropathy in Chinese patients with type 2 diabetes Oncotarget, 2017;8:(57): 96885-96892.
Kang P, Tian C, Jia C. Association of RAGE gene polymorphisms with type 2 diabetes mellitus, diabetic retinopathy and diabetic nephropathy. Gene. 2012; 500:1–9.
Raska I Jr, Raskova M, Zikan V, Skrha J. Prevalence and risk factors of osteoporosis in postmenopausal women with type 2 diabetes mellitus. Cent Eur J Public Health 2017; 25:3-10.
Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose metabolism and regulation: beyond insulin and glucagon, Diabetes Spectr, 2004;17:183–90.
Szablewski L. Glucose Homeostasis and Insulin Resistance, Bentham Science Publishers; 2011.
Jim Parker. glucose metabolism, energy production and regulation of cellular and whole-body metabolism, Journal of the Australasian College of Nutritional and Environmental Medicine Inc (ACNEM)2020;39(1).
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)
This work is licensed under a Creative Commons Attribution 4.0 International License.
